According to Zhitong Finance App, China Antibody-B (03681.HK) issued an announcement. On July 24, 2026, the company has granted 18026 million share options to 2 eligible persons in accordance with the share option plan adopted at the special shareholders' meeting held on October 26, 2022 and revised at the annual shareholders' meeting held thereafter on June 14, 2024. Each share option gives its holder the right to subscribe for one share of the company's shares. The share option grants the grantee the right to subscribe for a total of 18.026 million shares, which can only be realized after acceptance by the grantor.

According to Zhitong Finance App, China Antibody-B (03681.HK) issued an announcement. On July 24, 2026, the company has granted 18026 million share options to 2 eligible persons in accordance with the share option plan adopted at the special shareholders' meeting held on October 26, 2022 and revised at the annual shareholders' meeting held thereafter on June 14, 2024. Each share option gives its holder the right to subscribe for one share of the company's shares. The share option grants the grantee the right to subscribe for a total of 18.026 million shares, which can only be realized after acceptance by the grantor.